



*[Handwritten signature]*

**PATENT**

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

**In re Application of:**

Peeters et al.

**Serial No.:** 10/824,782

**Filed:** April 15, 2004

**For:** NEWCASTLE DISEASE VIRUS  
INFECTIOUS CLONES, VACCINES AND  
DIAGNOSTIC ASSAYS

**Confirmation No.:** 7153

**Examiner:** S. Hurt

**Group Art Unit:** 1648

**Attorney Docket No.:** 2183-4646.2US

**CERTIFICATE OF MAILING**

I hereby certify that this correspondence along with any attachments referred to or identified as being attached or enclosed is being deposited with the United States Postal Service as First Class Mail on the date of deposit shown below with sufficient postage and in an envelope addressed to the Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

February 5, 2008  
Date

*[Handwritten signature: Betty Vowles]*  
Signature

Betty Vowles  
Name (Type/Print)

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

In compliance with the duty to disclose information material to patentability pursuant to 37 C.F.R. § 1.56, it is respectfully requested that this Supplemental Information Disclosure Statement be entered and the documents listed on attached Form PTO/SB/08 be considered by the Examiner and made of record. Copies of any cited foreign patents, publications, or pending unpublished U.S. applications are enclosed pursuant to 37 C.F.R. § 1.98(a)(2).

Pursuant to 37 C.F.R. § 1.98(d), a copy of any patent, publication or other information listed in the Information Disclosure Statement is not required to be provided if it was previously cited by or submitted to the office in a prior application, provided that the prior application is

properly identified in the statement and relied upon for an earlier filing date under 35 U.S.C. § 120.

Accordingly, no copy of information marked with a pound sign (#) is enclosed because it was previously cited or submitted to the patent office in a prior application which is properly identified, and is relied upon for an earlier filing date. The references are as follows:

U.S. Patent Documents

<u>U.S. Patent No.</u>	<u>Publication Date</u>	<u>Patentee</u>
#US - 5,310,678	05-1994	Bingham et al.

Other Documents

#COLEMAN et al., Abstract, The Matrix Protein of Newcastle Disease Virus Localizes to the Nucleus via a Bipartite Nuclear Localization Signal, Virology, August 1993, Vol. 195, No. 2, pp. 596-607.

#KAWAHARA et al., Abstract, Distribution and substrate specificity of intracellular proteolytic processing enzyme(s) for paramyxovirus fusion glycoproteins, Journal of General Virology, 1992, Vol. 73, No. 3, pp. 583-90.

#MORISHIMA et al., A subunit of yeast site-specific endonuclease Scl is a mitochondrial version of the 70-kDa heat shock protein, The Journal of Biological Chemistry, September 1990, Vol. 265, No. 25, pp. 15189-97.

#RIETHDORF et al., Cloning, Nucleotide Sequence, and Expression of the Bacillus subtilis Ion Gene, Journal of Bacteriology, Nov. 1994, Vol. 176, No. 21, pp. 6518-27.

#DURBIN et al., Recovery of Infectious Human Parainfluenza Virus Type 3 from cDNA, Virology, 1997, Vol. 235, No.2, pp. 323-332.

#UMINO et al., Plaque Formation of Newcastle Disease Virus in Primary Chicken Kidney Cells, Behring Institute Mitteilungen, 1991, Vol. 89, pp. 59-66.

#WERNER et al., Characterization of avian paramyxovirus type 1 strains isolated in Germany during 1992 to 1996, Avian Pathology, Feb. 1999, Vol. 28, p. 79-88.

**Serial No.: 10/824,782**

#WEHMANN et al., Lentogenic field isolates of Newcastle disease virus in Canada and Hungary are identical with the vaccine type used in the region, Avian Pathology, Feb. 1999, Vol. 28, pp. 6-12.

#OHTO et al., A thermophilic cyanobacterium Synechococcus elongatus has three different Class 1 prenyltransferase genes, Plant Molecular Biology, 1999, Vol. 40, pp. 307-21.

#PHILLIPS et al., Nucleotide sequence of the 5'-terminus of Newcastle disease virus and assembly of the genomic sequence: Agreement with the "rule of six," Archives of Virology, 1998, Vol. 143, pp. 1993-2002.

#Pursuant to 37 C.F.R. § 1.98(d), copies of the previously identified documents are not being provided since they were previously cited by or submitted to the Office in the following prior application:

Serial No.: 10/788,232

Filed: February 26, 2004

For: NEWCASTLE DISEASE VIRUS INFECTIOUS CLONES, VACCINES AND NEW DIAGNOSTIC ASSAYS, which application is being relied upon for an earlier filing date under 35 U.S.C. § 120.

In compliance with the duty to disclose information material to patentability pursuant to 37 C.F.R. § 1.56, Applicants hereby identify the following listed copending applications naming a common inventor(s):

Attorney Docket No.: 2183-5238.1US

Serial No.: 11/717,293

Filing Date: 3/12/2007

Title: MOSAIC INFECTIOUS BURSAL DISEASE VIRUS VACCINES

Serial No.: 10/824,782

This Supplemental Information Disclosure Statement is filed after the mailing date of the first Office Action on the merits.

The fee pursuant to 37 C.F.R. § 1.17(p) is enclosed.

Respectfully submitted,



Allen C. Turner  
Registration No. 33,041  
Attorney for Applicants  
TRASKBRITT, P.C.  
P.O. Box 2550  
Salt Lake City, Utah 84110-2550  
Telephone: 801-532-1922

Date: February 5, 2008

ACT/bv

Enclosures: Form PTO/SB/08  
Cited Non-U.S. Patent Documents  
Check in the amount of \$180.00

Document in ProLaw